Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.

Employees - 32, CEO - Robert T. Connelly, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -18.39, Piotroski Score(max is 10): 2, Working Capital: $8971000, Total Assets: $22689000, Retained Earnings: $-245495000, EBIT: -38821000, Total Liabilities: $24126000, Revenue: $0

AryaFin Target Price - $0.26 - Current Price $ - Analyst Target Price $